Recent 8-K filings for MLTX

• June 1, 2026, 6:20 AM ET other material materiality 0.60 positive item 1.01

  MoonLake Immunotherapeutics signs commercial supply and capacity agreements with Vetter for sonelokimab

  Master Commercial Supply Agreement signed May 22, 2026 with Vetter for manufacturing pre-filled application systems.

• May 11, 2026, 7:59 PM ET regulatory materiality 0.85 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  MoonLake aligns with FDA on BLA for sonelokimab in HS; Q1 cash $357.9M

  FDA pre-BLA meeting positive; alignment on submission plans, adolescent data inclusion, and safety strategy.

• February 23, 2026, 6:59 PM ET other material materiality 0.75 positive item 1.01item 2.02item 2.03item 5.02item 7.01item 8.01item 9.01 ◈ Debt Financings◈ Material Agreements

  MoonLake reports positive Phase 2 axSpA data: 81% ASAS40 at Week 12; amends Hercules loan for up to $400M

  Phase 2 S-OLARIS trial: 81% of SLK-treated patients achieved ASAS40 response at Week 12 (n=26, mNRI).

• January 8, 2026, 6:59 PM ET regulatory materiality 0.85 positive item 8.01item 9.01

  MoonLake gets FDA clarity on SLK in HS; no new trials needed for BLA submission

  FDA confirms MoonLake can establish substantial evidence of effectiveness using existing VELA-1, VELA-2, and MIRA trials; no additional HS trials required.

• November 5, 2025, 6:59 PM ET other material materiality 0.70 neutral item 1.01item 9.01

  MoonLake Immunotherapeutics raises $75M in equity offering of 7.1M shares at $10.50/share

  Offering of 7,142,857 Class A ordinary shares at $10.50 per share for gross proceeds of $75M.

• November 5, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01

  MoonLake Q3 2025: $380.5M cash, positive Phase 2 PPP data for Sonelokimab

  Cash and equivalents $380.5M as of Sept 30, 2025; runway into H2 2027.

• September 29, 2025, 7:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  MoonLake VELA Ph3: VELA-1 meets primary HiSCR75 (p<0.001); VELA-2 misses but shows significance on treatment policy

  VELA-1 achieved HiSCR75 at week 16 with 34.8% vs 17.5% placebo, delta 17.3% (p<0.001).

• August 5, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  MoonLake Q2 cash $425M; Phase 3 HS readout expected Sept 2025

  R&D expenses Q2 $49.8M (up from $36.5M Q1) on trial ramp-up and BLA preparation.

• May 12, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  MoonLake reports Q1 2025 cash of $480.1M, secures up to $500M debt facility; Phase 3 HS enrollment complete

  Cash, cash equivalents and short-term marketable debt securities of $480.1M as of March 31, 2025.

• April 3, 2025, 7:59 PM ET debt materiality 0.78 positive item 1.01item 2.03item 7.01item 9.01

  MoonLake secures up to $500M non-dilutive loan from Hercules Capital; $75M drawn at close

  Up to $500M non-dilutive term loan facility from Hercules Capital; $75M funded at close on March 31, 2025.

• February 26, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  MoonLake reports FY 2024 net loss of $121.2M, cash of $448M; advances sonelokimab to Phase 3

  Net loss for 2024 was $121.2M, compared to $44.1M in 2023, driven by increased R&D spending.

• November 7, 2024, 6:59 PM ET other material materiality 0.75 positive item 2.02item 9.01

  MoonLake Q3 cash $493.9M; Phase 3 HS readout on track for mid-2025

  Cash, equivalents and short-term debt securities of $493.9M as of Sep 30; runway to end of 2026.

• August 7, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  MoonLake reports $519.8M cash; initiates Phase 3 VELA in HS, positive FDA/EMA feedback for PsA Phase 3

  Q2 2024 cash, equivalents and short-term debt securities of $519.8M; cash runway to end-2026 unchanged.

• June 10, 2024, 7:59 PM ET regulatory materiality 0.80 positive item 7.01item 8.01item 9.01

  FDA and EMA back MoonLake's Phase 3 program for sonelokimab in psoriatic arthritis

  FDA and EMA unanimously supported MoonLake's proposed Phase 3 IZAR program for sonelokimab in PsA.

• May 7, 2024, 7:59 PM ET other material materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  MoonLake Q1 cash $547.1M; positive FDA/EMA feedback for Phase 3 sonelokimab in HS

  Cash and equivalents $547.1M at March 31, 2024, expected to fund operations to end of 2026.

• March 11, 2024, 7:59 PM ET other material materiality 0.80 positive item 7.01item 8.01item 9.01

  MoonLake reports 24-week PsA data with ~60% ACR50; plans Phase 3 HS trials in Q2 2024

  ARGO trial: ~60% ACR50 at week 24; ~40% ACR70; >80% PASI90; ~60% PASI100; low discontinuation ~5%.

• February 29, 2024, 6:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01 ◈ Earnings Releases

  MoonLake FY 2023 net loss $44.1M; cash $511M; sonelokimab Phase 3 prep advances

  Cash, cash equivalents and short-term marketable debt securities $511.0M at Dec 31, 2023, up from $496M at Sep 30, 2023.

• February 26, 2024, 6:59 PM ET regulatory materiality 0.85 positive item 7.01item 9.01

  MoonLake gets FDA & EMA support for Phase 3 sonelokimab in hidradenitis suppurativa

  FDA and EMA both support Phase 3 design for sonelokimab (SLK) in HS; trial named VELA.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.75 · Most common event other_material

16 positive 0 negative 7 neutral

source · MLTX on sec.gov